Compare Vanguard Short Term Corporate Bond ETF (VCSH) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Short Term Corporate Bond ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Vanguard Short Term Corporate Bond ETF trades at $78.52, while State Street SPDR S&P Biotech ETF trades at $159.14. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| VCSH | XBI | |
|---|---|---|
Sector | Fixed Income | Broad Market / Factor |
52-Week High | $80.20 | $164.28 |
52-Week Low | $78.41 | $86.92 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VCSH trades at $78.59 with minimal daily movement (+0.13%). Technical indicators show a bearish trend with all moving averages signaling sell, though oscillators remain neutral. The ETF maintains a 4.8% yield but faces headwinds from tight credit spreads and an unattractive entry point according to recent analysis. Recent institutional activity shows mixed sentiment with both position increases and decreases.
The outlook remains cautious with limited upside potential due to current rate environment and credit spread compression. Key risks include interest rate sensitivity and competitive pressure from treasury-focused alternatives. Investors seeking short-term corporate bond exposure should monitor credit quality and duration management.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
